Atezolizumab with enzalutamide vs enzalutamide alone in metastatic castration-resistant prostate can...
Atezolizumab with enzalutamide vs enzalutamide alone in metastatic castration-resistant prostate cancer: a randomised phase 3 trial
About this item
Full title
Author / Creator
Powles, Thomas , Yuen, Kobe C. , Gillessen, Silke , Kadel, Edward E. , Rathkopf, Dana , Matsubara, Nobuaki , Drake, Charles G. , Fizazi, Karim , Piulats, Josep M. , Wysocki, Piotr J. , Buchschacher, Gary L. , Alekseev, Boris , Mellado, Begoña , Karaszewska, Bogusława , Doss, Jennifer F. , Rasuo, Grozdana , Datye, Asim , Mariathasan, Sanjeev , Williams, Patrick and Sweeney, Christopher J.
Journal title
Language
English
Formats
More information
Scope and Contents
Contents
Early clinical data indicate that some patients with castration-resistant prostate cancer (CRPC) may benefit from program death ligand-1 (PD-L1) inhibition, especially with enzalutamide. IMbassador250 (
NCT03016312
) enrolled 759 men with metastatic CRPC whose disease progressed on abiraterone. Adding atezolizumab to enzalutamide in an open l...
Alternative Titles
Full title
Atezolizumab with enzalutamide vs enzalutamide alone in metastatic castration-resistant prostate cancer: a randomised phase 3 trial
Authors, Artists and Contributors
Author / Creator
Yuen, Kobe C.
Gillessen, Silke
Kadel, Edward E.
Rathkopf, Dana
Matsubara, Nobuaki
Drake, Charles G.
Fizazi, Karim
Piulats, Josep M.
Wysocki, Piotr J.
Buchschacher, Gary L.
Alekseev, Boris
Mellado, Begoña
Karaszewska, Bogusława
Doss, Jennifer F.
Rasuo, Grozdana
Datye, Asim
Mariathasan, Sanjeev
Williams, Patrick
Sweeney, Christopher J.
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9406237
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9406237
Other Identifiers
ISSN
1078-8956
E-ISSN
1546-170X
DOI
10.1038/s41591-021-01600-6
